City
Epaper

Lupin contributes Rs 21 crore towards COVID-19 relief efforts

By ANI | Updated: April 11, 2020 10:50 IST

Pharma major Lupin Ltd on Saturday announced a contribution of Rs 21 crore for relief efforts directed towards mitigating the COVID-19 crisis.

Open in App
Pharma major Lupin Ltd on Saturday announced a contribution of Rs 21 crore for relief efforts directed towards mitigating the COVID-19 crisis.

Lupin's Global Giving Programme comprises of three separate contributions made by its employees, the company and the promoter family.

Lupin's employees have contributed by giving two days of their individual salaries, together contributing a sum of Rs 5.5 crore to the Prime Minister's Citizen Assistance and Relief in Emergency Situations Fund (PM CARES Fund).

Lupin has matched an equal sum of Rs 5.5 crore for direct initiatives that the company will implement to support overburdened national and state healthcare systems through the donation of personal protective equipment, medicines and providing meals for front-line workers and the needy.

In addition, the promoter Desh Bandhu Gupta family has committed a sum of Rs 10 crore for other direct impact initiatives in India and elsewhere in the world to supplement Lupin's relief efforts to tackle the COVID-19 crisis.

"As one of the leading pharmaceutical compes globally, Lupin remains committed to ensure uninterrupted supply of medicines across India and global markets while ensuring safety of our personnel involved," said Managing Director Nilesh Gupta.

"We are grateful for this opportunity to support those who are at the front-line of this battle against COVID-19," he said in a statement.

Lupin is an innovation-led transnational pharmaceutical company which develops and commercialises a wide range of branded and generic formulations, biotechnology products and active pharma ingredients in over 100 markets in the United States, India, South Africa and across Asia Pacific, Latin America, Europe, and Middle East regions.

Lupin is the third-largest pharmaceutical company in the United States by prescriptions and in India by global revenues. It has a leadership position in the cardiovascular, anti-diabetic and respiratory segments besides a significant presence in the anti-infective, gastro-intestinal, central nervous system and women's health areas.

( With inputs from ANI )

Tags: Lupin LimitedGlobal giving programmeindiaasia
Open in App

Related Stories

MumbaiUniversity of Bristol Chooses Mumbai for Its First Overseas Campus, Set to Open in September 2026

NationalRaksha Bandhan 2025: Now You Can Send a Rakhi to Your Brother in India Post's Waterproof Envelope — Here's How to Track Your Parcel

NationalGold in Dubai Cheaper Than India: Pricing, Rules, and Import Limits Explained

NationalIndia Spends ₹1.38 Lakh Crore Annually on Edible Oil Imports

International‘This Might Hit You Hard’: NATO Chief Mark Rutte's Warning to India, China, and Brazil Over Russia Ties Amid Ukraine War

कारोबार Realted Stories

BusinessDPIIT ieam visits Bengaluru to boost IoT and Deep-Tech innovation

BusinessIndia's smartphone exports hit record $7.72 billion in Q1FY26, Apple leads with $6 billion

BusinessGujarat ranks 2nd in marine fish production, estimated to be 10.37 lakh MT in 2024-25

Business'Untrue': RBI has not asked banks to stop disbursing Rs 500 notes from ATMs by Sep, says govt

BusinessShivraj Chouhan echoes PM Modi’s call to buy India-made goods